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THE BENEFITS OF THERAPEUTIC HYPOTHERMIA IN POST-CARDIAC 
ARREST VICTIMS 
MIRIAM FAHIM  
ABSTRACT 
Cardiac arrest is a phenomenon in which a sudden loss of heart function 
leads to cessation of blood delivery to the rest of the body. It is one of the leading 
causes of natural death in the United States. Because its onset cannot be 
predicted, therapy for post-cardiac arrest victims focuses on management of 
moderate organ failure and neurological injury. The mortality rate of out-of-
hospital cardiac arrest victims remains about 90%, but currently, there are 
several management techniques that reduce the incidence of sudden cardiac 
death. My goal is to argue that despite some of the negative effects of 
therapeutic hypothermia, it holds the most promise to sustain organ and 
neurological recovery.  
 This study focuses on evaluating the pathophysiology of post-cardiac 
arrest syndrome, and referencing literature that documents the reversal 
techniques of therapeutic hypothermia. Despite the side effects and unwanted 
consequences that come with targeted temperature management, there is an 
imbalance between the benefits and consequences, resulting in enhanced 
recovery when this technique is carefully administered shortly after the cardiac 
arrest episode.  
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INTRODUCTION 
Cardiac arrest is among the leading causes of natural death in the U.S. It 
is responsible for approximately half of all heart disease related deaths, and 
nearly 325,000 adults deaths in the U.S. each year. Sudden death due to cardiac 
arrest is typically the result of organ failure or neurological damage, therefore 
cardiac-arrest management following successful resuscitation focuses on limiting 
the progression of these consequences.   
In the first part of this thesis, we will describe the implications of cardiac 
arrest, its mechanisms, and its consequences. We will discuss the 
pathophysiology of post-cardiac arrest syndrome, and various treatment 
modalities. Second, we will explore the history and the clinical relevance of 
targeted temperature management (TTM), our choice of treatment modality, and 
review previous studies documenting its therapeutic uses. Finally, we will assess 
the efficacy of therapeutic hypothermia in reversing the effects of post-cardiac 
arrest syndrome following successful resuscitation efforts. 
 
Implications of Cardiac Arrest   
 Cardiac arrest is defined as an impaired cardiac output and failure of the 
heart to adequately pump blood to the rest of the body, leaving vital organs 
impaired of oxygen.  During cardiac arrest, blood circulation ceases and oxygen 
delivery to vital organs is reduced. This has the greatest effect on the brain, and 
the victim immediately loses consciousness as their breathing shallows. The 
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longer cardiac arrest remains untreated, the more permanent the brain damage 
that results, and the more severe the degree of sepsis and vital organ failure. 
Approximately 95% of patients that suffer from out-of-hospital cardiac arrest die 
from sudden cardiac death either because resuscitation efforts such as CPR and 
were unavailable at the time of cardiac arrest, or due to ineffective post-cardiac 
management following successful resuscitation.  
 
Diagnosis and Mechanisms of Cardiac Arrest  
 
Arrhythmias, hypertrophic cardiomyopathy, structural heart disease, and 
undiagnosed coronary artery disease lead to ventricular fibrillation, and are 
among the leading causes of cardiac arrest. If the victim is successfully 
resuscitated by cardiopulmonary resuscitation and use of a defibrillator, the 
resulting extent of damage in victims is dependent on the amount of time the 
patient goes untreated i.e., the amount of time that vital organs are deprived of 
oxygen. Immediate consequences range from shock, high fever, and biological 
disorders, to severe brain injury and poor neurological prognosis. 
Fatigue, syncope, chest pain, and palpitations are among the many 
symptoms that may indicate and precede cardiac arrest. Because the onset of 
cardiac arrest cannot be predicted, diagnostic tests are instead performed to 
assess patients at risk for cardiac arrest, or following the attack to investigate the 
underlying cause and to help prevent future episodes. Investigations performed 
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to diagnose cardiac arrest include coronary catheterization, electrocardiograms 
(ECG), and echocardiogram. 
Ventricular fibrillation (VF) is the most commonly identified arrhythmia, and 
can result in cardiac arrest.  Ventricular fibrillation is a cardiac rhythm disturbance 
in which the ventricles contract in a rapid unsynchronized pattern. These erratic 
electrical impulses cause the ventricles to quiver, rather than pump blood to the 
rest of the body. Figures 1 and 2 show ECG examples of normal and atrial 
fibrillation.  
 
 
Figure 1 – Normal ECG 
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Figure 2 ECG of Ventricular Fibrillation 
 
 
Myocardial infarction (MI) is among the leading causes of ventricular 
fibrillation and occurs when the flow of oxygenated blood to a section of the 
heart’s muscle is blocked and consequently, the heart muscle begins to die. 
Typically the result of coronary artery disease, an MI can occur and trigger 
ventricular fibrillation and sudden cardiac arrest by causing tissue infarction. The 
tissue dies due to irreversible necrosis of heart muscle secondary to prolonged 
oxygen deprivation. The infarction caused by MI leaves behind areas of scar 
tissue that causes electrical short circuits around the scar – resulting in 
abnormalities in the heart rhythm. Diagnosis of MI is based on the patient’s 
symptoms such as discomfort and pressure in the chest, ECG to assess heart 
rhythm, and blood tests to monitor levels of heart enzymes and troponins.   
Disturbances that occur within the sinus node are clinically reflected as 
arrhythmias. The sinus node is the heart's natural pacemaker, and contraction of 
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the heart muscles is a result of electrical impulses generated by the cluster of 
sinus node cells in the right atrium of the heart (Figure 3). These electrical 
impulses flow through the heart - synchronizing the contractions of the ventricular 
muscular wall. This machinery controls the coordinated pumping of blood from 
the heart to the rest of the body. When the flow of electrical impulses through the 
heart is hindered, the delivery of oxygenated blood to vital organs of the body is 
impaired and cardiac arrest results.  
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Figure 3 Sinoatrial Node and the Heart’s Electrical Impulses 
 
The heart’s electrical rhythm originates from the sinoatrial node in its right apex, and 
travels to the atrioventricular node, to the AV bundle, to the L. and R. bundle branches, 
through the Perkinje fibers, and towards the left ventricle. The generates the rhythmic 
contraction of the heart and when this does not work correct, heart arrhythmias results 
and lead to cardiac arrest and often times, sudden cardiac death.  
    
 
Primary heart rhythm abnormalities are intrinsic electrical problems in the 
heart that do not involve the heart muscle or valves. Brugada syndrome and long 
QT syndrome are ion channelopathoies that cause ventricular fibrillation, which 
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leads to cardiac arrest. Patients with Brugada syndrome have an increased risk 
of abnormal heart rhythms from the lower chambers of the heart, ie. ventricular 
arrhythmias, which exhibit a type 1 Brugada ECG pattern. Similarly, long QT 
syndrome is an electrical abnormality that causes fast and irregular heartbeats. 
When the heart beats erratically for a long period of time, results in cardiac arrest 
and sudden cardiac death. An electrocardiogram (ECG) is typically given 
following cardiac arrest to reveal disturbances in heart rhythm or detect 
prolonged QT syndrome and other arrhythmias. 
 
 
Figure 4 Normal v. Long QT Syndrome  
 
Hypertrophic cardiomyopathy occurs when the cells of heart's muscular 
walls undergo hyperplasia and/or hypertrophy. As the muscular walls thicken, the 
ability of the heart to pump blood is impaired due to the weakening of the left 
ventricular wall. Cardiac arrest results when the ejection fraction of the left 
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ventricle is reduced, and the heart is unable to adequately pump blood to the rest 
of the body. Diagnosis of cardiomyopathy can be made by an ECG or 
echocardiogram, which is the gold standard for diagnosis.  
Blood vessel abnormalities also contribute to ventricular fibrillation and as 
a result, may lead to cardiac arrest. The stretching or enlargement of heart 
valves causes a tightening or weakening of the valves characteristic of valvular 
heart disease. This increases the risk of developing arrhythmia and ultimately, 
cardiac arrest and sudden cardiac death result due to poor oxygenation to the 
body’s vital organs.  
Coronary artery disease is the most prevalent heart disease and is the 
most common cause of death in the United States. When the coronary arteries 
that supply blood to the heart muscle become hardened and narrowed due to a 
buildup of materials such as fatty deposits and scar tissue, they form atheromas 
on the heart wall. As plaque accumulates within the vessel, less blood is able to 
flow through the arteries. As a result, the heart muscles are deprived of oxygen 
which may lead to chest pain and myocardial infarction. If coronary heart disease 
remains untreated, heart failure and arrhythmias results and may also lead to 
cardiac arrest and sudden cardiac death.  
 
Resuscitation   
 
Although death can result within minutes of cardiac arrest and loss of 
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heart function, cardiopulmonary resuscitation (CPR) may reverse early 
pathologies associated with cardiac arrest. CPR procedure involves restoration 
of blood circulation, clearance of the victim’s airway, and breathing for the 
victim.  Use of a defibrillator following CPR commonly increases patient 
prognosis due to the reversal of ventricular fibrillation, as discussed below.   
Chest compressions help resolve impaired blood circulation, thus restoring 
oxygenation of vital organs and the brain. Although restoring cerebral perfusion is 
crucial for brain function, it is important to note that restoration of spontaneous 
circulation to the brain worsens neurological prognosis, as described in the 
Pathophysiology of Post-Cardiac Arrest Syndrome section.   
Clearing of the victim’s airways is achieved by using the head-tilt, chin-lift 
maneuver, and breathing for the victim is achieved by mouth-to-mouth breathing. 
Mouth-to-mouth breathing involves applying a positive pressure to the airway to 
ensure oxygenation of the blood. The purpose of CPR is to keep oxygenated 
blood flowing, and to preserve brain function until a more definitive medical 
treatment can restore the normal heart rhythm. The use of an automated external 
defibrillator (AED) applied to the chest is an electrical therapy that stops the 
arrhythmia and allows the heart to reestablish its normal rhythm.   
Less than eight percent of out-of-hospital cardiac arrest (OHCA) victims 
survive to hospital discharge. This depends on whether CPR and defibrillation 
were provided within 5-7 minutes following the attack. If bystander CPR is 
available, the survival rate following cardiac arrest increases by approximately 
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40%.  Achieving earlier defibrillation also results in a greater percentage of 
survivors in cardiac arrest victims with shockable rhythms (Kern, 2015).   
 
Pathophysiology of Post-Cardiac Arrest  
 
The extent of the complications experienced by post-cardiac arrest victims 
who have been successfully resuscitated depends on the delay of the initial 
resuscitation treatment, the efficacy of resuscitation, and the time elapsed 
between collapse and return of spontaneous circulation (Mongardon et al., 
2011).  Due to the profound impact of CPR, the survival rates to hospital 
discharge has improved drastically over the past several decades.  
The pathophysiology of post-cardiac arrest syndrome involves the initial 
loss of blood flow followed by a global ischemia reperfusion phenomenon, and a 
nonspecific activation of the systemic inflammatory response. The intensity of 
events experienced during post-cardiac arrest syndrome depends on the 
duration of “no flow” and “low flow” phases. Resulting multiple organ failure, post-
cardiac arrest shock, and neurological failure dominate the clinical picture in 
patients who are successfully resuscitated from cardiac arrest.   
The ischemic phase of post-cardiac arrest syndrome involves a brief 
period of no flow, and is followed by longer reperfusion, or low flow period (Figure 
6). The initial "no flow" phase is primarily responsible for the cellular and tissue 
damage that occurs during post-cardiac arrest syndrome. Reduced oxygen 
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delivery is typically offset by lower systemic metabolic needs. However, if there is 
no compensated reduction of both oxygen delivery and metabolic requirement, 
e.g. when cell metabolism requirements remain high or when the ischemic period 
is prolonged, there is reduced ATP synthesis relative to what is required by 
individual cells, and cellular function is interrupted.   
Reperfusion occurs 4-6 minutes following the "no flow" phase (Figure 6). 
Blood flow and O2 delivery may be spontaneously restored, or may be the result 
of resuscitation efforts such as CPR. During this period, ATP stores are 
completely depleted which leads to plasma membrane depolarization and the 
opening of voltage-gated calcium channels. Ultimately, this calcium influx into the 
cytoplasm that causes cellular and tissue damage (Figure 5). A prolonged 
depletion of cellular O2 delivery results in anaerobic respiration and oxidative 
stress, characterized by lactic acid and free fatty acid accumulation. Loss of ATP 
stores and the resulting oxidative stress further damages cellular membranes 
and impairs pump function within cells.   
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Figure 5 Ca2+ Entry into the Cell  
Ca2+ flow into cells through open NMDA receptors results in the degradation of cell 
membranes and proteins, as well as an increase in ROS.  
 
 
Increased calcium concentration, hypoxia and the subsequent recovery of 
blood flow during reperfusion events results in the formation of radical oxygen 
species (ROS) (Figure 6). Hydroxyl radical (• OH) is the most destructive free 
radical as it causes cell death by inactivating cytochromes, introducing lipid 
peroxidation, and altering membrane transport proteins. Inactivation of 
cytochromes reduces cellular respiration, resulting in reduced ATP production 
and further impairing cellular function. Lipid peroxidation is the process by which 
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free radicals remove electrons from lipids in cell membranes - directly causing 
cellular damage, primary necrosis, and apoptosis. Alteration of membrane 
transport proteins leads to neurological damage and impairment of cognitive 
abilities. Other free radicals such as hydrogen peroxide (H2O2) and superoxide 
anion (• O2-) also cause functional and structural lesions within cells.   
 
 
 
Figure 6 Consequences of impaired blood flow  
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ROS also aggravate the clinical consequences of post-cardiac arrest 
syndrome by reducing anti-oxidant activity and enhancing a pro-oxidant state, 
thereby causing major endothelial toxicity. The damaged endothelium shifts the 
pathological state towards one of systemic inflammation as cytokines are 
produced, complement is activated, and chemotaxis of neutrophils occurs and 
initiates the inflammatory cascade. Clinical features of the systemic inflammatory 
response includes increased heart and respiratory rate, and an elevated white 
blood count. Severe sepsis is characterized by organ dysfunction, hypotension or 
hypo perfusion, and involves lactic acidosis, oliguria, and acute mental status 
changes.   
Post-cardiac arrest shock is characterized by low cardiac output and a 
normal to low left filling pressure, leading to multiple organ failure. When a victim 
is in shock, his or her organs are deprived of blood and oxygen due to an overall 
reduction in ejection fraction from the left ventricle. If untreated, this can lead to 
permanent organ damage or death, caused by cardiocirculatory dysfunction.   
Multiple organ failure (MOF) is the direct result of post-cardiac arrest 
shock, caused by sequestration of activated neutrophils in organs such as the 
lungs, liver, kidney, and the brain. Inappropriate activation of neutrophils within 
the microvasculature results in the pathological manifestations of multiple organ 
failure. Infiltrating neutrophils produce ROS and release additional pro-
inflammatory cytokines such as IL-6, TNF-alpha, and chemokines such as 
monocyte chemoattractant protein-1 (MCP-1). Increases in these factors 
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amplifies the inflammatory response in these organs. For example, inflammation 
of the lungs following cardiac arrest indicates respiratory failure as characterized 
by (Nielsen, 2010) pulmonary edema, lung contusion, atelectasis, or aspiration. 
This results in hypoxia, cardiogenic shock, acute renal failure, and liver failure. 
(Adrie, 2005) Acute kidney injury occurs in approximately 40% of cardiac arrest 
victims, while respiratory dysfunction occurs in approximately half of patients 
resuscitated from cardiac arrest.   
Ultimately, the ischemic-reperfusion phenomenon is responsible for the 
activation of the systemic inflammatory response as plasma cytokine levels and 
circulating endotoxins are increased, and the clinical picture is markedly similar 
to what is observed in septic patients. In fact, there has been found to be a 
marked activation of coagulation in patients following cardiopulmonary 
resuscitation and restoration of blood flow. Activation of the systemic 
inflammatory response and the coagulation cascade leads to multiple organ 
failure and puts victims at risk for delayed neurological recovery by enhancing 
coagulation, thrombosis, and capillary permeability (Moran, 2006).   
The systemic inflammatory response contributes to shock and multiple 
organ failure via the activation of the pro-inflammatory cytokines interleukin-1 (IL-
1), interleukin-6 (IL-6), and tumor necrosis factor (TNF). The inflammatory 
response is associated with increased coagulation activity, reduced 
anticoagulation, and inhibited fibrinolysis (Adrie, 2005). Thrombin is generated, 
which converts fibrinogen to a fibrin clot - impairing blood flow and further 
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aggravating oxygen delivery to vital organs. These abnormalities are more 
severe in victims who die within two days of cardiac arrest, and even more 
pronounced in patients who die from early refractory shock– thus indicating the 
causative nature of coagulation in aggravating post-cardiac arrest shock 
and sudden cardiac death (Moran, 2006).  
  
 
   
Figure 7 Blood Coagulation in vivo  
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Shock is associated with reduced levels of anticoagulation factors Protein 
C and Protein S, and increases in thrombomodulin, which is a cofactor for 
thrombin. Reduced anticoagulation factors and increased coagulation factor 
availability upregulates the coagulation cascade - further contributing to the 
stagnant blood flow experienced during post-cardiac arrest syndrome. Major 
coagulation abnormalities are consistent with secondary down-regulation of the 
protein C receptor pathway - via the down-regulation of protein C receptors, 
thereby reducing levels of Activated Protein C (APC). At a molecular level, APC 
is responsible for activation of anti-coagulation by proteolytically activating Factor 
Va and Factor VIIIa so that prothrombin is converted into thrombin. Thrombin 
then converts fibrinogen into fibrin, which stabilizes the cross-linked fibrin clot 
(Figure 7). Protein C is an endogenous protein which enhances fibrinolysis, limits 
thrombin generation, and modulates the inflammatory response. However, during 
reperfusion and the resulting state of shock, protein C levels are reduced, and 
coagulation is enhanced (Figure 8).  
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Figure 8 APC Concentration change following resuscitation 
Upon admission, victims of cardiac have normal concentrations of APC. As reperfusion 
occurs, the APC concentration decreases, which results in decreased fibrinolysis and 
increased coagulation.  
 
 
The mortality observed following cardiopulmonary resuscitation is likely 
linked to downregulation of the activated protein C anticoagulant pathway, 
secondary to protein C depletion and increased thrombosis, as well as an 
increased systemic inflammatory response. While shock related deaths are 
common, neurological failure remains the most common cause of death in 
patients resuscitated from post-cardiac arrest. In fact, organ failure caused by 
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systemic inflammation can also delay neurological recovery due to resulting 
reduced cerebral perfusion.   
Neurological injury is characterized by neurocognitive deficits, learning, 
and memory impairment (Xiang, 2016). Specifically, neurological damage is 
caused by ischemic injury initiated during the “no flow” phase, and is aggravated 
further during reperfusion periods and CPR. During the no flow phase, cerebral 
activities are compromised. During the reperfusion period, neurological damage 
increases drastically and becomes permanent if not reversed soon after trauma. 
Fewer than 10% of patients admitted to the hospital after successfully 
resuscitated OHCA are discharged without severe neurological impairments. 
These impairments progress to a post-anoxic vegetative state and ultimately, 
sudden cardiac death if the underlying pathogenic mechanisms causing 
neurological damage are not addressed. (Bernard, 1997) Specifically, it is the 
activation of the inflammatory cascade and the immune response that is 
responsible for neurological damage during reperfusion phases. As cerebral 
oxygen delivery is reduced and demand is increased, cerebral edema and 
increased intracranial pressure worsen, resulting neurological ischemia.   
The mechanisms causing neurological injury parallel that of organ failure 
and subsequent shock, including cell membrane and pump dysfunction, 
leukocyte and inflammatory cell infiltration, high concentrations of ROS, and 
release of cytokines and proinflammatory mediators (Bernard, 1997). Membrane 
and pump dysfunction is caused by depleted ATP stores secondary to calcium 
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influx, lactic acidosis, and oxidative stress.  During oxygen deprivation, ATP 
production is unable to keep up with ATP consumption, which initiates 
biochemical cascades that lead to cell necrosis. Specifically, an ATP deficit leads 
to Na+/K+ pump dysfunction and mitochondrial damage, which leads to 
increased intracellular calcium levels. This contributes to immediate cellular 
necrosis and apoptosis due to the triggered release of glutamate, an excitatory 
neurotransmitter. Glutamate binds the NMDA receptors in the brain, which 
triggers an even greater calcium overload by opening more calcium channels. 
Excessive calcium entry also directly generates ROS and excitotoxic enzymes 
such as endonucleases, ATPases, and phospholipases. These enzymes further 
contribute to cell membrane damage and pump dysfunction. As phospholipase 
breaks down the cell membrane, the cell becomes more permeable to harmful 
chemicals and ions flow into the cell.  
The reperfusion period also directly results in the generation of oxygen 
free radicals from oxidative metabolism - thus reducing iron Fe3+ to Fe2+. 
Reduced iron participates in the formation of more oxidizers, which injures 
cellular membranes even further. As the production of ROS increases within 
brain cells such as microglia and astrocytes, sequestration of neutrophils results 
and pro-inflammatory mediators are released. 
Victims successfully resuscitated from post-cardiac arrest are also at an 
increased risk for infectious issues, secondary to complications caused by the 
cardiac arrest during the reperfusion period (Levi, 2003). Two thirds of cardiac 
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arrest survivors present with infectious complications - likely caused by loss of 
airway protection, pulmonary contusion, mechanical ventilation, BBB interruption, 
and ischemia-reperfusion injury during cardiac arrest.  Neurons are damaged by 
the upregulation of cytokines and adhesion molecules, which results in the 
disruption of the blood brain barrier (BBB) (Kvietys, 2012). The brain becomes 
increasing susceptible to infection, which can result in further neurological 
damage. Cerebral edema also results due to the leakage of large proteins 
through the damaged BBB. The swollen brain causes compression, and further 
damages the brain tissue.  
 
Treatments and Management of Post-Cardiac Arrest  
 
Following successful resuscitation, therapeutic management for post-
cardiac arrest victims has three primary motives: to determine and treat the 
underlying cause of cardiac arrest, to treat resulting shock and organ failure, and 
to optimize cerebral protection. Management therapy focuses on treating the 
underlying pathologies caused by the return of spontaneous circulation, as this is 
the primary origin of shock, organ failure, and neurological damage.   
The cause of cardiac arrest can be determined by the various diagnostic 
tests previously described. A range of long term treatments such as 
percutaneous coronary intervention and implantable cardioventricular 
defibrillators (ICD) are prescribed depending on the cause of cardiac arrest. 
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Additionally the use of a defibrillator to restore heart rhythm immediately following 
arrest is has been shown to double the survival of post-cardiac arrest victims.  
 
Treatment of Shock 
 
Post-resuscitation shock is typically reversible within 48 - 72 hours, and 
treatment modalities are similar  those of inflammatory shock due to acute heart 
failure (Nielson, 2010). In order to reverse the effects, ventricular contractility 
must be restored and measures must be taken to correct hypoxemia, 
hypotension, and reduced tissue oxygenation. Among patients with cardiac 
arrest, it has been shown that combined vasopressin-epinephrine and 
methylprednisolone therapies during cardiopulmonary resuscitation improve 
survival to hospital discharge, and even have a favorable neurological prognosis. 
Epinephrine is therapeutic for shock victims because it causes the veins to 
constrict thereby increasing blood flow, and reduces swelling in airways so that 
breathing returns to normal.  
If the cause of cardiac arrest is coronary artery disease, it is necessary to 
correct the source of the hemodynamic disturbance. Coronary angioplasty or 
coronary artery bypass are procedures that involve restoring coronary blood flow. 
By inserting a catheter through a blood vessel and inflating a small balloon at the 
site of the atheroma, restoration of blood flow is achieved when the balloon is 
inflated to compress the atheroma against the blood vessel wall. In coronary 
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artery bypass surgery, one healthy vessel from the body is grafted to the blocked 
coronary vessel so that flow bypasses the blocked segment of the coronary 
artery. Thus, a new path is created for oxygenated blood to flow to heart muscle 
and the symptoms of shock are reduced.    
 
Treatment of Organ Failure  
 
Treatment of multiple organ failure, secondary to impaired organ 
oxygenation and post-cardiac arrest shock, requires the restoration of blood flow. 
This is achieved by chest compressions during CPR, and therapies that interrupt 
the underlying pathogenesis of post-cardiac arrest syndrome. Such therapies 
target the coagulation cascade. Thrombolytic therapy for example, is used an 
immediate treatment for thrombosis and upregulation of the coagulation cascade 
by dissolving blood clots and restoring blood flow. The most commonly used 
therapeutic drug is tissue plasminogen activator (tPA), which catalyzes the 
conversion of plasminogen to plasmin - the major enzyme responsible for 
fibrinolysis (Figure 9). Administration of Factors XIa or XIIa are also used for this 
enzymatic conversion and clot breakdown, as shown in Figure 9. Administration 
of Protein C can also serve the same effects as these fibrinolytic enhancers, as it 
specifically reduces the activation coagulation pathway itself.  
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Figure 9 The Fibrinolytic Cascade 
Fibrinolysis is the process that prevents blood clots from growing and interfering with 
blood flow.  Because the activation of the coagulation cascade is upregulated during 
shock and organ failure phenomenon, it is important to administer therapies to reverse 
the effects of coagulation. Thus, administration of tPA activates downstream products of 
the fibrinolytic cascade to dissolve the blood clots formed as a result of reperfusion. 
  
 
Treatment of Anoxic Brain Injury   
 
While shock and organ failure dominate the initial clinical picture of post-
cardiac arrest syndrome, it is the optimization of the cerebrum that confers 
greatest long-term protection for post-cardiac arrest victims. Most patients remain 
unconscious after ROSC because of the severity of the brain injuries sustained 
during the reperfusion period. The degree of neurological impairments that 
dictates the prognosis of post-cardiac arrest victims and thus, neuroprotection is 
necessary to limit neurological consequences so that these patients can survive 
to hospital discharge.   
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Because increased levels of calcium and over activation of NMDA 
receptors triggered by glutamate release is linked to neurological injury caused 
by the downstream effects of excitotoxicity, it was believed that neuroprotection 
could be conferred by administration of calcium channel blockers or glutamate 
antagonists. However, there has been no argument for routine use of these as 
neuroprotective drugs. Rather, medications are given for management, rather 
than reversal of anoxic brain injury (Xiang, 2016). Steroids are given to reduce 
cerebral swelling secondary to brain anoxia – however, at the expense of further 
damage of the brain.   Barbiturates may also be given to allow brain tissue time 
to recover during the anoxic insult, as well as anti-seizure medication. 
Cannabinoids have also been found to exert some antioxidant effects.  
Neurological impairment worsens during the inflammation caused by 
reperfusion and CPR – thus, promising reversal therapeutic interventions are 
those that exert anti-inflammatory effects and treat neurological deficits during 
this phase. Induction of hypothermia for example, has been found to be an 
effective treatment because it targets the pathophysiological events and slows 
down the ischemic cellular cascades during ROSC.   
Long term management of anoxic brain injury can be achieved with 
targeted temperature management (TTM) techniques - specifically, induction of 
therapeutic hypothermia (TH) has been consistently found to confer protective 
neurological effects. Hypothermia is protective when it is induced before or 
during an anoxic insult because the brain tends to reach a higher temperature 
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during periods of oxygen deprivation. For example, hypothermia is used for 
cerebral protection during operations involving cardiopulmonary bypass, in order 
to preserve neurological function.   
Though the mechanism remains unclear, therapeutic hypothermia is 
effective in delaying neurological damage when it is induced shortly after trauma, 
as it reverses the effects of the early inflammatory response during the 
reperfusion phase (Mongardon, 2011). It decreases cerebral metabolism, 
reduces apoptosis and mitochondrial dysfunction, slows the cerebral excitatory 
cascade, decreases the local inflammatory response, and reduces ROS 
production. There is also evidence that it decreases the resulting cerebral edema 
during cardiac arrest, further delaying neurological impairment (Zhang, 2016).   
Because the mechanism of action of therapeutic hypothermia with regards 
to inflammatory and the immune responses remains unclear, it is important to 
supplement this treatment method with other neuroprotective therapies to ensure 
the efficacy of TH. Minocycline, a tetracycline derivative, has been shown to be 
neuroprotective for victims of stroke. In the same respect, it inhibits activation 
and proliferation of microglia, migration of neutrophils, and release of other 
proinflammatory cytokines in for post-cardiac arrest victims (Plane, 2010). 
Statins, a 3-hydroxy-3 methylglutaryl reductase inhibitor, has also been shown to 
provide neuroprotective effects following cerebral ischemia. The use of this 
coenzyme in conjunction with therapeutic hypothermia may ameliorate oxidative 
stress and improve endothelial function by attenuating the inflammatory response 
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(Vaughan et al., 1999) Similarly, molecular hydrogen has been shown to have 
therapeutic effects for cerebral ischemic injury through its antioxidant and anti-
inflammatory mechanisms of action. (Hayashida, 2012).  
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Specific Aims  
  
Specific Aims of the following thesis include:   
1. Comprehensive review of literature to characterize the nature of post-cardiac 
arrest syndrome. 
2. Investigation into the current evidence for TTM use. 
3. Conclusion of the efficacy of TTM in predicting positive outcomes for post-
cardiac arrest victims.  
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PUBLISHED STUDIES  
 
 Uses of Targeted Temperature Management  
 
 
Normal body temperature is maintained at a core temperature of 36.5– 
37.5∘C through thermoregulation, but it can deviate depending on external or 
internal conditions. Hypothermia is defined as having a core temperature <35ºC, 
and most persons do not survive core temperatures < 28°C. While hypothermia 
is a known cause of death in cold climates, mild to moderate hypothermia has 
been used for centuries to preserve life in warranted situations. In Ancient 
Greece, physicians induced hypothermia in trauma patients to control 
hemorrhage. In one early instance of hypothermia induction intended for 
neurological protection, the patient was cooled to < 30°C. Although neurological 
function was restored, numerous systemic complications arose. It has been 
shown however, that inducing milder hypothermia 32°C - 34°C is beneficial, as it 
minimizes extraneous complications meanwhile restoring cerebral function. 
Today, induced hypothermia is also used in comatose cardiac arrest survivors, 
head injury, neonatal encephalopathy, and to preserve neurological function 
during cardiopulmonary bypass operations (Polderman, 2015).  
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Figure 10 Therapeutic hypothermia improves survival after cardiac arrest  
 
 
Figure 11 Long term Outcomes of Targeted Temperature Management  
GOS – Glasgow Outcome Scale – Degree of Recovery Scale 
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Although the exact mechanism of action of therapeutic hypothermia 
remains unclear, there are several established effects that exert protection by 
reversing the pathologies associated with neurological ischemia. Of the greatest 
significance is the reduction of cerebral metabolism, which causes the brain to 
consume less O2 and glucose. It is known that cooling the core temperature by 
one degree Celsius decreases cerebral metabolism by 6-8%, and reduces the 
amount of oxygen required by the brain. Hypothermia decreases heart rate and 
slows the metabolism, which decreases the cardiac afterload and oxygen 
demand (Luscombe, 2006). Because a lesser concentration of O2 and glucose 
are available under conditions of neurological ischemia, hypothermia is 
therapeutic because it balances O2consumption and availability, thereby 
minimizing the deleterious neurological effects.  
Of great clinical significance is the effect of hypothermia on the reduction 
of calcium overload and free radical formation. Because free radicals directly 
cause endothelial injury, it is important to reduce their formation to better the 
prognosis of post-cardiac arrest survivors. ROS are responsible for the rupture of 
the outer mitochondrial membrane and subsequently, the release of pro-
apoptotic proteins such as cytochrome c (Alva, 2013). Hypothermia reverses the 
calcium overload caused by ischemia and thus, reduces cellular necrosis and 
apoptosis. The mechanism involves the blockage of the cell signaling pathway of 
necrosis and apoptosis, and upregulation of protective genes following ischemia 
(Zhao et al., 2007). Experimental assays have shown that when hypothermia is 
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applied during an ischemic episode, it inhibits pro-apoptotic molecules and 
induces an increase in anti-apoptotic molecules in ischemic—affected tissues 
(Figure 12) (Eberspa ̈cher, 2003).  
Caspases are a family of protease enzymes that initiate programmed cell 
death and inflammation. While neurological ischemia increases caspase activity, 
directly hypothermia inhibits it and thus, minimizes neurological tissue necrosis. 
Reduction of neurocyte apoptosis in the hippocampus for example, has been 
shown to prevent memory deficits associated with hypoxemia (Alva, 2013)  
 
Figure 12 Modulation of Apoptosis by Hypothermia  
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Hypothermia also suppresses the inflammatory cascade by decreasing 
cytokine production, meanwhile reducing leukocyte migration within neurocytes 
to restrain the upregulation of the inflammatory response initiated by hypoxia 
(Figure 13) (Dufner et al, 2016). This not only protects the victim from 
neurological damage, but also from remote organ injury (Gunderson et al., 2001). 
This was learned from an experiment in which hypothermia was applied to rats 
induced into hemorrhagic shock via the withdrawal of blood. Relative to the 
control group, the hypothermic rats’ organ injury was ameliorated, as reflected by 
the decreased levels of plasma markers of organ function: alphaGST, and 
creatinine. Overall, the survival rate of the hypothermic rats was greater than the 
normothermic control group by over 16%.  
 
FIGURE 13 Leukocyte count: TTM v. No TTM (141)  
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FIGURE 14 Cytokine and Chemokine profiles of patients during cooling (0-
72 hours) and rewarming phases (72-114 hours) 
 
Neuronal injury following ischemic episodes is also associated with 
activation of N-methyl-D-aspartate (NMDA) receptor due to enhanced glutamate 
efflux and reduction of glutamate uptake. Increased levels of glutamate results in 
neuronal excitotoxicity by binding NMDA receptors, which is mediated by 
ischemic activation of voltage-gated calcium channels. It is hypothesized that 
hypothermia improves ionic homeostasis and reduces neurotoxicity by providing 
a means of NMDA receptor blockage (Nishizawa, 2001). Although the exact 
mechanism is unknown, induction of hypothermia is correlated with reduced 
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calcium concentrations and accordingly, reduced extracellular glutamate 
concentrations. 
Techniques for Inducing Hypothermia 
 
 
Obtaining the accurate core temperature in post-cardiac arrest victims is 
crucial because body temperatures above the target may not provide sufficient 
neuroprotection, while overcooling beyond the target temperature typically 
produces systemic complications. Invasive and non-invasive techniques exist to 
cool the core body temperature, and each technique has its own advantages and 
disadvantages. In general, endovascular cooling techniques have the benefit of 
obtaining a more accurate target temperature, at the expense of being more 
invasive. The standard procedure for endovascular cooling is to insert a catheter 
with a 30 ml kg-1 crystalloid solution chilled to 4°C, and infuse it into the patient’s 
veins for 30 mins. This technique is known to drop the core temperature by 
approximately 1.7 degrees. It is a fast, efficacious, and safe method – but it does 
not maintain the patient at cool temperatures (32-34°C) for longer than 3-4 hours 
without rewarming (Kliegel, et al., 2007). 
In general, the goal is to allow the body to cool for 12-24 hours. In order to 
maintain the cooled temperature for several hours, it is necessary to utilize 
additional cooling techniques. Repeated administration of cold infusions would 
result in fluid overload and cardiac decompensation. However, less invasive 
techniques such as applying icepacks to major blood vessels and cooling 
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blankets has been shown to adequately supplement endovascular cooling 
techniques to maintain the targeted temperature (Kliegel, et al., 2007). On their 
own however, these non-specific techniques tend to cause unintentional 
overcooling, resulting in other systemic complications (Caulfield, 2011).     
 
 
Benefits and Consequences of TTM  
 
 
Although TTM has been shown to significantly improve the prognosis of 
cardiac arrest survivors and reduce the extent of neurological ischemic damage, 
there are several side effects that must be considered when employing this 
technique. Studies have found that the extent of these complications depends on 
the duration of cooling and the deviation from a core target temperature of 32-
34°C. Prolonged hypothermia and cooling beyond 32°C tends to increase the 
degree of metabolic rate and inflammatory response suppression, and electrolyte 
imbalance. Following TTM, rewarming occurs and unavoidably reverses the 
therapeutic effects of hypothermia. This phase resembles hypoxia, as there is an 
increased production of oxygen free radicals, and metabolism is increased.  
The goal of TH is for neurological preservation to balance out against 
systemic side effects. Endovascular cooling achieves an accurate and controlled 
temperature for TTM, so it is the preferable method of TH induction. However, it 
results in whole-body hypothermia - which influences all organ systems. 
Hypothermia has specific therapeutic effects on neurological injury, but it can 
have negative effects on various systems including the cardiovascular, 
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respiratory, renal, hemodynamic, and bone marrow systems if overcooling occurs 
(Luscombe, 2006).  
Mild hypothermia can cause ECG changes such as an increased PR 
interval, the appearance of an Osborn wave, and a widening of the QRS 
complex. These arrhythmias typically occur when the temperature is dropped 
below 30 degrees, and the therapeutic effect of hypothermia is counteracted as 
these arrhythmias result in ventricular fibrillation and ultimately, cause cardiac 
arrest (Luscombe, 2006).  
 It is also known that temperatures below 32 degrees increases the 
incidence of pulmonary complications (O’Phelan, 2015). Cool core temperatures 
suppress the immune system by downregulating complement activation and 
inhibiting the release of cytokines. If hypothermia is prolonged (>24 hours), the 
patient’s risk for infection increases because the immune system’s response to 
foreign invaders is weakened, and the risk for pneumonia for example, is greatly 
increased.  
Cold diuresis is also observed during the induction phase of therapeutic 
hypothermia. Cool temperatures cause the ascending Loop of Henle to absorb 
less solute, and diuresis results. Peripheral vasoconstriction cause by cool 
temperatures also increases the core fluid volume. This increases the mean 
arterial pressure, and induces a diuretic response. As the circulatory temperature 
decreases, the solubility of gases in blood also increases. Thus, the affinity of 
hemoglobin for oxygen increases, and respiratory alkalosis can result (Figure 
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15).  
 
 
Figure 15 Hemoglobin-oxygen affinity increases under hypothermic 
conditions  
Left shift of the curve causes respiratory alkalosis, reduced offloading of O2, which 
further impairs O2 delivery  
 
 
Hypothermia reveres the hemodynamic disturbances initiated by cardiac 
arrest by inhibiting the coagulation cascade and improving blood flow. This 
inhibits the formation of micro thrombi in the brain but at the same time, this can 
increase patients’ bleeding risk. Depending on whether or not the patient has a 
traumatic injury or is bleeding, this can have detrimental effects due to increased 
blood loss. In vivo experimental results indicate that temperatures below 35°C 
can induce platelet dysfunction. Below 33°C, the activation of clotting enzymes in 
the coagulation cascade can also be inhibited. However, the clinical effects tend 
to be minor, and typically only present an issue when the patient has 
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experienced a traumatic injury or is actively bleeding (Polderman, 2012).  
Hypothermia also affects the bone marrow’s production of blood cells. 
Under hypothermic temperatures, platelets leave the circulation and bleeding 
time is lengthened due to the reduced number and function of platelets. White 
cell count also decreases, further aggravating a state of immunosuppression 
under hypothermic conditions (Luscombe, 2006).  
Most studies assessing the reversal effects of hypothermia have been 
conducted on animal models. In one study, the long term effects of induced 
hypothermia on the inflammatory response in pigs was assessed. Levels of 
inflammatory cytokines such as IL-6 and IL-10 were measured during early and 
late posttraumatic phases. Although there are significant anti-inflammatory 
effects of induced hypothermia during early and late phases, rewarming occurs 
during the late posttraumatic phase and is associated with an increased 
inflammatory response. It was found that increases in the inflammatory response 
occurred as the concentrations of pro-inflammatory mediators increased and 
anti-inflammatory mediators decreased. Therefore, it can be reasoned that 
therapeutic effects of hypothermia cannot be sustained for long periods of time. 
(Alva, 2013). Relative to normothermic controls, the imbalance of pro and anti-
inflammation associated with hypothermic conditions and inevitable rewarming 
contributes to systemic complications, which appears to have a negative effect 
on the mortality of multiple trauma patients treated with TTM. However, when 
multiple trauma patients were compared against cardiac arrest victims, TH 
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resulted in an overall improved outcome following ischemia and reperfusion 
secondary to cardiac arrest (Horst, 2016). 
If TTM techniques are unavailable up to 24 hours following trauma, it may 
not present any therapeutic effects. In previous studies, inducing hypothermia 48 
hours following trauma conferred no benefits as leukocyte count decreased, but 
neurological function was not preserved. Therefore, the incidence of infection 
increased due to a suppression of the inflammatory response, with no added 
benefit.  
It has been reasoned that the benefits of TTM on neurological injury due 
to cardiac arrest should be the same, regardless of the underlying cause of 
cardiac arrest. However, in one study (Leão, 2015), the survival rate of cardiac 
arrest victims with various etiologies were compared following TTM. It was found 
that among the causes of cardiac arrest, myocardial infarction is associated with 
the highest probability of survival and the best neurological outcomes. Thus, the 
potential risks and benefits of TTM is generally not the same across all causes of 
cardiac arrest (Nielson et al., 2014) 
 
The TTM Trial and Target Temperature 
One issue regarding use of TTM, is the deliberation over the most optimal 
target temperature. Although international guidelines recommend a temperature 
of 32° to 34°C, this data has been deduced from experiments performed on 
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animals (Colbourne, 1994). In the international TTM trial (Nielsen, et al.) 
published in the New England Journal of Medicine, 950 unconscious adults after 
out-of-hospital cardiac arrest were randomly assigned to targeted temperature 
management groups at either 33°C or 36°C (Figure 13, Table 1). The outcomes 
of interest in this study included an all-cause mortality by the end of the trial, and 
composite of poor neurological function or death at 180 days, evaluated with the 
Cerebral Performance Category (CPC) scale and the modified Rankin scale 
(mRS).  
The Cerebral Performance Category Scale (graded 1-5) classifies the 
neurological status and interprets outcome among survivors of cardiac arrest. 
The modified Rankin scale (graded 1-6) is used to measure the degree of 
disability of individuals who have suffered neurological damage (see appendix I 
for scale parameters). At the three-month follow-up, 54% of the patients in the 
33°C group did not make it to hospital discharge following TTM and scored 
poorly on the CPC scale. In the group assigned to 36°C TTM, 52% of patients in 
the group died or had poor neurological function. Because similar mortality rates 
were observed between moderate and mildly cooled groups in humans, the 
degree of cooling according to international guidelines has been challenged.  
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Figure 16 Probability of Survival for TTM 33°C v. 36°C 
 
 
Table 1 CPC and mRS comparison of TTM 33°C v. 36°C  
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Best Outcomes of Targeted Temperature Management  
 
Relative to other causes of cardiac arrest, TTM has the best outcome on victims 
of myocardial infarction. Therapeutic hypothermia appears to be beneficial in this case 
because it reduces infarct size, microvascular resistance and reperfusion injury (Kang, 
2016). In a prospective study investigating the prognostic factors associated with 
survival to discharge in OHCA victims, it was found that a shockable rhythm, and a 
shorter time to return of spontaneous circulation were also associated with better 
outcomes (Sathianathan, 2016). 
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DISCUSSION AND CONCLUSION 
 
The International Liaison Committee on Resuscitation guidelines on 
hypothermia after cardiac arrest, recommends that patients with OHCA and a 
shockable rhythm be cooled to 32°C - 34°C, for 12 to 24 hours. Cooling between 
32°C - 34°C has been shown to preserve neurological function, meanwhile 
limiting other systemic complications. However, these guidelines are based on in 
animal in vivo and in vitro studies. The novel 2013 TTM trial based on human 
subjects showed that there is no difference between mild (36°C) and moderate 
(33°C) cooling. Thus, further studies should aim to investigate TTM at different 
degrees in human subjects.  
The effectiveness of TTM therapy appears depend on source of the injury 
– as victims of cardiac arrest have a higher survival rate after TTM induction than 
other subgroups. Within cardiac arrest victims, cardiac arrest secondary to 
myocardial infarction shows the highest rate of recovery compared to other 
causes. Because myocardial infarction is the most common cause of cardiac 
arrest, TTM induction has been linked to good outcomes.  
  TTM use is strongly supported by pathophysiological evidence. 
Hypothermia reduces metabolic demand and ischemic-reperfusion injury – 
thereby reducing the effects of excitotoxicity, ROS formation, BBB disruption, 
necrosis, and apoptosis. Analysis of cytokine and chemokine profiles in animals 
shows a reduction of inflammatory mediators – thus indicating the mechanism by 
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which therapeutic hypothermia likely attributes its success. Additionally, TH has 
been shown to downregulate the activation of the coagulation cascade. Again, 
future studies should aim to analyze these profiles in humans, in order to make a 
conclusion regarding its effectiveness in increasing the survival of cardiac arrest 
victims.  
  In order to confer the greatest benefit, TH must be carefully administered. 
Care must be taken for precision cooling so that the patient’s core temperature 
does not drop below 32°C. Additionally, possible non-cardiac arrest factors must 
be taken into consideration. If the cardiac arrest victim is also a multiple trauma 
patient or is actively bleeding for example, cooling below 35°C can proliferate 
systemic side effects and induce platelet dysfunction. These effects counteract 
preservation of neurological function, and reduce the likelihood of a positive 
outcome.  
Furthermore, the best outcomes for cardiac arrest victims occur when TH 
techniques are employed shortly after the cardiac arrest episode. The 
effectiveness of TH is also related to whether or not the victim has a shockable 
initial rhythm and a shorter ROSC time. Despite the many factors that must be 
considered, TTM is a widely used therapy that proves to be therapeutic for a 
condition with a <10% survival rate.  Future studies should aim to investigate 
human subjects and induce therapeutic hypothermia on cardiac arrest victims at 
different durations and degrees. If it were possible to cool only the brain, this 
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could provide information as to whether or not this would produce a better or a 
worse prognosis, than cooling the whole body.  
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APPENDIX 
Cerebral Performance Scale (CPS)
 
 
Modified Rankin Scale (mRS) 
 
 
 
 
 
 
mRS Score Definition  
0 No symptoms 
1 No significant disability. Able to carry out usual activities, 
despite some symptoms 
2 Slight disability. Able to look after own affairs without 
assistance, but unable to carry out all previous activities.  
3 Moderate disability., Requires some help, but unable to 
walk unassisted.  
4 Moderate severe disability. Unable to attend to own bodily 
needs without assistance, and unable to walk unassisted.  
5 Severe disability. Requires constant nursing care and 
attention, bedridden, incontinent.  
6 Dead 
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